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With the fast paced advancement of modern medicine, cancer treatments have improved greatly 
over the past few decades; however, the overall survival rate has not improved for head neck 
squamous cell carcinoma (HNSCC). Traditionally, the general affected population of HNSCC 
was male over 50-60 years of age, whom have had history of alcohol and tobacco use. 
Conversely, in the recent decades, HNSCC has exhibited significant rise in younger patients, 
largely due to the increase in human papillomavirus (HPV) infection among young adults.  
Generally, HPV as the most prevalent sexually transmitted disease, consisted of strains that do 
not cause harm to humans. Only handful of strains were found to be carcinogenic, potentially. 
Furthermore, the carcinogenic property of HPV has been increasing tremendously, and becoming 
a greater threat to human. For instance, HPV is the leading cause of cervical cancer currently. 
Recently, HPV related HNSCC has showed significant increase in the last 30 years as well, with 
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oropharyngeal squamous cell carcinoma (OPSCC) as the most prevalent type, and the most 
increased kind in the HPV related HNSCC groups. 
In this study, three methods of survival analysis were used which included non-parametric 
Kaplan-Meier method, parametric accelerated failure model and Cox proportional hazard method 
to achieve this data analysis.  
First, two best fitted predictive survival models were developed for HNSCC (OPSCC) patients 
whom have been diagnosed and treated at Barnes Jewish Hospital in St. Louis. The models were 
initially determined by forward and backward selection of Cox proportional hazard method. The 
best predictive variables were further identified via forward selection in Kaplan Meier method. 
As a result, the final model estimates were obtained through accelerated failure time model.  
Additionally, using Kaplan Meier method, HPV and HNSCC (OPSCC) relationships were 
investigated via P16 protein presence, which is an indicator of HPV related OPSCC. Survival 
rate of P16+ and P16− status were compared and contrasted. Interaction between the presence of 
P16 protein and other factors such as age groups, tobacco use, loco-regional fail, various stages 
of cancer defined by tumor differentiation, cancer recurrence, and lymph node found positive for 
cancer were explored.   
Lastly, other factors of interest such as types of treatment, types of chemotherapy, race and 
anemia were investigated for overall survival rate as well as interactions with presence or 
absence of P16, also using Kaplan Meier method. Survival graphs were generated for the whole 
model as well as for the group comparisons.  
!
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Chapter 1: Introduction 
1.1 Head and Neck Squamous Cell Carcinoma (HNSCC) 
1.1.1 Overview 
As the seventh most common cancer, approximately affecting 600,000 people worldwide and 
accounts for 3% of all cancers, head and neck squamous cell carcinoma (HNSCC) is defined as 
cancers which affect squamous cells in the mucosa membranes around the nose, mouth and 
throat region. More specifically, the regions include the oral cavity, oropharynx, nasopharynx, 
larynx, and hypopharynx [18].  
HNSCC affects male around 50-60 years old historically. However, recently cancer cases of 
younger people are on the rise. Around 75% of HNSCC are the result of tobacco and alcohol use, 
which mostly are within the older group [10,11]. Recently, Human Papillomavirus (HPV) is 
becoming a significant factor that can increase the chance of developing HNSCC.  
1.1.2 Characteristics 
Depending on the causations of HNSCC, this cancer utilizes different carcinogenic pathways. 
HNSCC associated with tobacco and alcohol use is characterized by P53 mutation, and more 
prevalent in older patients over the age of 50-60 years old. While HNSCC associated with HPV 
is characterized by P16 mutation, which resulted in the increase of P16 protein expressions. A 
protein called E7 in HPV causes pRb degradations, which leads to the overexpression of P16 
protein in the host [ 4, 5, 23].  
Several indications or significant factors are related to HNSCC. For none-HPV related HNSCC 
group, characteristics include anemia, tobacco and alcohol use, ACE27 index, and race have 
been found significant in this subgroup [1, 2, 21]. Anemia is characterized by reduced red blood 
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cell count, hemoglobin (Hgb), and hematocrit, which is another way to measure red blood cell 
count. It has been previously found to be prevalent within the HNSCC population, and suspected 
to be related to the presence of cancer or comorbid diseases. Also anemia is traditionally 
correlated to smoking which is the cause for P53 related (non-HPV related) cancer [1, 2]. One 
way to access comorbidity mentioned above is the Adult Comorbidity Evaluation-27 (ACE27). 
ACE27 is an index that ranks the severity of comorbidity, which is defined as the presence of 2 
diseases simultaneously. Study has found that P16− patients exhibit more comorbid diseases than 
P16+ group. In the study, 43.3% of P16− patients had severe disease compared to a much less 
percentage of P16+ patients. Comorbidity was also found to be more prevalent in current 
smokers in the same study [8,13].  
1.1.3 Treatment 
Several treatments are available for HNSCC. First and the most prevalent treatment is primary 
surgery to remove the tumor, others include chemotherapy (CT), chemo-radiation therapy (CRT) 
and radiation therapy (RT). Initially, the typical treatment suggested by physicians is primary 
surgery, unless the cancer tumor is miniscule, in which case, CT, RT, or CRT is recommended. 
Following primary surgery, CT, RT or CRT is often suggested as follow-up treatment.  
Furthermore, Chemotherapy treatment consists of a group of drugs which target cancer cells. 
Within Chemotherapy, there are induction chemotherapy and concurrent chemotherapy for this 
current study [17].  
Moreover, the goal of RT is to deliver a lethal dose of radiation to the target tissue and 
consequential surroundings.  Several radiation therapies were conducted for the study which 
included various types of intensity modulated radiation therapy (IMRT), external beam treatment 
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involving emission of photon or electron, or combination of both, and definitive radiation 
treatment [15].  
Lastly, CRT is the combination of CT and RT, which is found to be effective for HNSCC 
(OPSCC). Many times, doctors would offer a combination of above treatments to optimize 
patient’s chance at survival [15, 16].  
1.2 Human Papillomavirus (HPV)  
1.2.1 Overview 
Human Papillomavirus (HPV) comprises of a group of DNA viruses which have the potential to 
infect basal epithelial cells, both skin and mucosal layer. HPV consists of ~200 strains, and 
estimated to be the most prevalent sexually transmitted disease. Certain strains of HPV are able 
to trigger genital warts, and various types of cancers such as cervical cancer, penile cancer, 
oropharyngeal cancer and others. However, only a small percentage of the strains are associated 
with genital warts and cancers. More specifically, about 40 strains can infect the genital, mouth, 
and throat area in men and women.  furthermore, the strains that is responsible for genital warts 
are different from the ones that cause cancer [7].  
1.2.2 Disease Statistics 
How prevalent is HPV? According to CDC, about 79 million Americans are infected with HPV, 
and 14 million are infected each year. HPV has been the leading cause of cervical cancer in 
women, and it is predicted to affect approximately 500 thousand women worldwide [18, 23]. The 
carcinogenic property of HPV is increasingly becoming a greater risk for HNSCC and described 
successively. 
1.3 HNSCC Risk and HPV 
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1.3.1 Overview 
HPV related HNSCC is at a steadily incline for the pass 30 years, which contributed to increase 
cancer risk of young individuals with HPV infection, especially male. HPV is detected in about 
¼ of all HNSCC, with majority of them being oropharyngeal squamous cell cancer (OPSCC) 
which is one of the most rapid growing cancer currently [6, 9].  
1.3.2 Influential Factors 
Recent studies have shown that HPV is associated with various types of head and neck squamous 
cell carcinoma (HNSCC), with OPSCC as the most increased and consists of majority of the 
HPV related HNSCC group. Furthermore, cancer risk is more prevalent in developing country 
compared with developed countries [7]. In table 1, different types of HPV related cancer and the 
relating statistics are presented below: 
 
                                                                                          Table 1 Adapted from Parkin et al. 2002 
The table above consists of cancer statistics up to 2002, which is concurrent with the time frame 
which this present study was conducted. However, HPV related HNSCC (OPSCC) is much 
higher by 2016.  
HPV can be identified via the overexpression of P16 protein in HNSCC (OPSCC), as mentioned 
in 1.1.2. P16 has established as surrogate marker for HPV+/ OPSCC patients. However, the 
identification is not limited to P16 prevalence. In a study of 496 patients done by Robinson et al. 
720 Bulletin of the World Health Organization | September 2007, 85 (9)
Policy an  practice
Human papillomavirus and HPV vaccines FT Cutts et al.
duration of immunity after natural in-
fection are not known. Only 50–60% 
of women develop serum antibodies to 
HPV after natural infection.4
Early HPV infections may be ac-
companied by mild changes in the epi-
thelium that are detectable by screening 
using virological and/or cytologic l ech-
niques, allowing early treatment. Cyto-
logical examination of cervical smears 
can detect abnormal growth of squa-
mous cells called squamous intraepi-
thelial lesions (SIL) f low or high 
grade, depending on how much of the 
cervical epithelium is affected and how 
abnormal the cells appear. Cervical in-
traepithelial neoplasia (CIN) is a term 
for abnormal cells in the cervix that are 
detected by histological examination 
of cervical biopsies; grades from 1 to 3 
are used to describe the proportion of 
the thickness of the cervical epithelium 
composed of abnormal cells seen in 
the histology section. In CIN 3, ab-
normal cells span greater than 2/3s of 
the cervical epithelium.  Similar grad-
ings exist for vaginal (VaIN 1–3) and 
vulvar (VIN 1–3) lesions. As the viral 
infection persists, it integrates into the 
human DNA and can lead to cancer 
precursors: moderate or severe cervical 
intra-epithelial neoplasia (CIN 2, CIN 3 
or adenocarcinoma in situ (AIS), often 
grouped together as CIN 2/3 or AIS). If 
these remain untreated, they have a high 
chance of leading to cancer.5
The main burden of HPV-related 
disease is due to cervical cancer. HPV 
was estimated to cause 100% of the 
almost 260 000 deaths from cervical 
cancer worldwide in 2005 (http://www.
who.int/healthinfo/statistics/bodprojec-
tions2030/en/index.html). About 80% 
of cancer cases attributable to HPV were 
in developing countries (Table 1).
The highest estimated incidence 
rates are in sub-Saharan Africa, Mela-
nesia, Latin America and the Caribbean, 
south-central Asia and south-east Asia.
In the most developed countries, 
the primary economic burden of HPV 
disease is related to the early detection 
and management of precancerous le-
sions.6 Not all developed countries have 
successfully controlled their cervical 
cancer burden through screening and 
early treatment programmes.7
The epidemiology of HPV 
infection
There have been many studies world-
wide on the proportion of cervical 
cancer, high- and low-grade squamons 
interaepithelial lesions (HSIL and LSIL) 
due to different HPV genotypes,8–12 but 
there are some gaps in Central Asia, 
Africa and Eastern Europe. With the 
possible exception of Europe, the same 
eight HPV genotypes were the most 
frequent in each region. The relative 
observed prevalence of HPV genotypes 
31, 33, 35, 45, 52 and 58 differed by 
region. These types cause a much lower 
proportion of all HPV infections and 
low-grade cervical lesions. For example, 
in a recent meta-analysis of HPV type 
distribution among women with LSIL, 
among 5910 HPV-positive LSIL lesions; 
the most common types were HPV 16 
(26%), 31 (12%), 51 (11%), 53 (10%), 
56 (10%), 52 (9%), 18 (9%), 66 (9%), 
and 58 (8%). Many other HPV types 
were also detected and multiple infec-
tions were frequent.13
Genital HPV infection is primarily 
transmitted by genital skin-to-skin con-
tact, usually but not necessarily during 
sexual intercourse.14–16 HPV infection 
can occur at any age and has been re-
ported in healthy young children.17 In 
a cross-sectional study of nearly 20 000 
women aged 15–74 years without cer-
vical lesions,18 age-standardized HPV 
prevalence varied more than 10-fold 
between populations. There is an in-
verse relationship between age and hu-
man papillomavirus (HPV) prevalence 
in many countries, but in some of the 
poorest areas studied HPV prevalence 
was high across all age groups.18 In some 
countries, cross-sectional and cohort 
studies have shown a U-shaped curve 
with a first peak in women under 30 
years of age and a second peak in women 
aged 55–64 years.14
Among women infected with HIV, 
a recent meta-analysis found that almost 
40% of those with no cervical cytologi-
cal abnormalities had HPV infection.19 
Simultaneous infection with multiple 
HPV genotypes is more common in 
HIV-infected women than in women 
without HIV. HIV-infected men and 
women are at increased risk of HPV-
associated anal cancer.20
HPV infection risk is associated 
with the number of sex partners that 
the woman or her partner has had over 
a lifetime and recently.21–23 Although 
some cross-sectional studies found no 
evidence of a reduction in HPV preva-
lence through condom use,23–25 lower 
HPV prevalence has been reported 
among women using condoms with 
their regular partners26 and a longitudi-
nal study found that consistent condom 
use protected American college students 
significantly against new HPV infections 
and appeared to protect against CIN le-
sion development.27 A protective effect 
against HPV infection and cervical can-
cer incidence has also been reported for 
women with circumcised partners.28
HPV vaccines
HPV vaccines are prepared from empty 
protein shells called virus-like particles 
Table 1. HPV-infection attributable cancer in 2002: developed and developing countries
Site Attributable to HPV (%) Developed countries Developing countries
Total cancers Attributable to HPV Total cancers Attributable to HPV
Cervix 100 83 400 83 400 409 400 409 400
Penis 40 5 200 2 100 21 100 8 400
Vulva, vagina 40 18 300 7 300 21 700 8 700
Anus 90 14 500 13 100 15 900 14 300
Mouth > = 3 91 200 2 700 183 100 5 500
Oro-pharynx > = 12 24 400 2 900 27 700 3 300
All cancers 5 5 016 100 111 500 5 827 500 449 600
Adapted from: Parkin et al.,7 with permission from Elsevier Sciences.
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have found that only 5% were HPV−/P16+, and 8% were HPV+/P16−. P16− negative patients 
were significantly more frequently anemic than p16+positive patients [2, 24].  
Additionally, studies have shown that P16+ patients have better survival rate than P16− patients 
for HNSCC (OPSCC) subgroup. Also, P16+ patients are usually younger with better socio-
economic status than P16−; since P16+ is associated with HPV related cancer rather than alcohol 
and tobacco related which can have an impact on socio-economic status [5, 9, 22]. 
Difference in race has also been found amongst HNSCC patients. For HPV+/P16+ group, 
Caucasian (67%) was found to be more prevalent then African American (25%) patients. Other 
study has found that HNSCC has worse mortality rate for African American Patients compared 
with Caucasian patients [3].  
1.4 Survival Analysis 
1.4.1 General View of Survival Analysis 
One question arises regarding Survival Analysis is why should one choose this form of analysis 
versus ordinary least squared and/or other regression methods. The answer lies within the 
inability of ordinary regression models at handling censored or truncated data. Conversely, 
survival analysis has the capability to handle the influence of time, and censored or truncated 
data. Survival analysis is designed to investigate time at which an event occurs (event time). The 
events typically involve death of an individual, incidence of certain disease, failure of machinery 
and other similar natured occurrences.  
In survival analysis, three common types of censoring are often discussed, which are left, right 
and interval censoring.  Right censoring is when an observation is dismissed before the event 
happens. Left censoring is when the event of interest has happened before the data is collected. 
Interval censoring is when an observation has happened during the time of the study, however 
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without knowing the exact time, thus lost the ability to be present in the dataset. Right censoring 
occurs more frequently than left censoring in survival analysis. 
One attribute of survival analysis is the ability to calculate hazard, and is essential to survival 
analysis. The hazard function is shown below: 
             Equation 1 
The goal of hazard function is to calculate instantaneous risk that an event will happen at time t.  
From the hazard function, the survival function can be formulated. The survival function 
calculates the probability of an individual surviving beyond a given time t. A simple form of the 
survival function is presented by: ! " = $%& − ℎ ) *)+,                          Equation 2 
Furthermore, three methods are most popular amongst survival analysis, which are Kaplan Meier 
method, accelerated failure time model, and Cox proportional hazard method. They are described 
subsequently[12, 19].  
1.4.2 Survival Models 
Regression Kaplan-Meier Method  
Kaplan Meier method is a non-parametric, one sample method, which does not assume a 
distribution. It measures survival probability over time, without making assumption of 
proportionality. 
In Kaplan Meier method, the Kaplan Meier (KM) estimator is a widely used tool, especially in 
biomedicine. This method is the default function of Proc Lifetest in SAS [12, 14, 19]. KM 
estimator is a nonparametric maximum likelihood estimator, also known as the product limit 
estimator. KM estimator is defined as: 
CHAPTER 2 Basic Concepts of Survival Analysis 
16 
Chapter 3, “Estimating and Comparing Survival Curves with PROC 
LIFETEST,” explains how to estimate survivor functions using life-table 
and Kaplan-Meier methods. Often, the objective is to compare survivor 
functions for different subgroups in a sample. If the survivor function for 
one group is always higher than the survivor function for another group, 
then the first group clearly lives longer than the second group. If survivor 
functions cross, however, the situation is more ambiguous.  
Probability Density Function  
When variables are continuous, another common way of describing 
their probability distributions is the probability density function, or p.d.f. 
This function is defined as 
 dt
tdS
dt
tdFtf )()()( ==  (2.1) 
That is, the p.d.f. is just the derivative or slope of the c.d.f. Although this 
definition is considerably less intuitive than that for the c.d.f., it is the 
p.d.f. that most directly corresponds to our intuitive notions of 
distributional shape. For example, the familiar bell-shaped curve that is 
assoc ated with the normal distribution is given by its p.d.f., not its c.d.f. 
Hazard Function 
For continuous survival data, the hazard function is actually more 
popular than the p.d.f. as a way of describing distributions. The hazard 
function i  defined as 
  
t
tTttTtth
t '
t'+d=
o'
|Prlim)(
0
 (2.2) 
Instead of h(t), some authors denote the hazard by O(t) or r (t). 
Because the hazard function is so central to survival analysis, it is worth 
taking some time to explain this definition. The aim of the definition is to 
quantify the instantaneous risk that an event will occur at time t. Because 
time is continuous, the probability that an event will occur at exactly time 
t is necessarily 0. But we can talk about the probability that an event 
occurs in the small interval between t and t + 't. We also want to make this 
probability conditional on the individual surviving to time t. Why? 
Because if individuals have already died (that is, experienced the event), 
they are clearly no longer at risk of the event. Thus, we want to consider 
only those individuals who have made it to the beginning of the interval 
[t, t + 't). Thes  considerations point to the numerator i  equation (2.2):  
Pr(t ≤ T<t+'t|T ≥t).  
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 - " = 1 − /0102:+;5+  Such that:  t1≤t≤tk           Equation 3 
The equation presents that at any given time t, the estimator is all the events that occurred during 
the elapsed time from 1to j. This basically is a survival estimate of the conditional probability of 
starting time to end time tj+1. Another way to look at the equation is: 
  - " = 1, " > "81 − *9:99:"9≤" , " ≤ "8            Equation 4 
This means that when t>tk, the result is 1; otherwise, the equation can be estimated via the KM 
estimator.                 
Another advantage of the Kaplan Meier method is the ability to test over various strata. When 
strata are being examined, the KM estimator separates the result table by each stratum, and 
survival graphs provide a curve for each stratum for comparison, which is mentioned later in the 
section. Within stratified Kaplan Meier method, 3 tests are available for the hypothesis testing, 
and illustrated in the subsequent analysis. The tests are log rank, Wilcoxon, and -2 log (LR).  
Log Rank test is the most widely used and the equation is defined as: (*=2 − $=2)?2@=                Equation 5 
This equation presents that the sum of all the event times in all strata over total time r.  
Wilcoxon test only differ from the log rank test by multiplying by n (sample number) and given 
by: :2(*=2 − $=2)?2@=                Equation 6 
This implies that the Wilcoxon test is a weighted test, which results in giving the earlier event 
more weight compared with later events. This test is more powerful when the event time possess 
a log-normal distribution. 
! 8!
Lastly there is the −2log (LR) test. This test can be biased because it assumes that the hazard 
function is constant in every group, and has an exponential distribution [12, 19]. 
Despite the fact that it’s only one sample, Kaplan Meier has many advantages, for example, the 
ability to generate survival graphs. The two graphs available are the product limit survival graph 
and the negative log-log survival graph. The product limit survival graph is a step like graph that 
shows survival probability at a give time t. The latter is just a simple negative log-log 
transformation (ABC −ABC!(")  to the survival probability, and a log transformation for time. 
This transformation makes the step-like product limit graph more interpretable when graphed 
with strata. Both graphs are great at illustrating models with strata. The differences between 
strata can be seen and interpret visibly.  
Accelerated Failure Time (AFT) Model 
The accelerated failure time model (AFT) is a parametric model, which has the underline 
assumption that the model follows some known distribution, such as binomial, Poisson or normal 
distribution. The advantage of assuming a distribution is the ability to see the shape of the hazard 
functions, which can make subsequent inferences easier to obtain. Another benefit of AFT model 
is that it can accommodate left and interval censoring while Cox’s proportional hazard model 
which is mentioned in the next section can only handle right censoring. 
In SAS, the AFT model is built within Proc Lifereg and all the models within are calculated 
based on maximum likelihood method.   The specific maximum likelihood method that Proc 
Lifereg uses is the Newton Raphson algorithm which is defined as: 
              Equation 7 
This algorithm estimates the covariance matrix of the coefficients.  
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The vector of first derivatives )(βU is sometimes called the gradient 
or score, while the matrix of second derivatives )(βI  is called the Hessian. 
The Newton-Raphson algorithm is then 
 )()(11 jjjj βUβIββ

+ =  (4.4) 
where I-1 is the inverse of I. In practice, we need a set of starting values 
 β0, which PROC LIFEREG calculates by using ordinary least squares, 
treating the censored observations as though they were uncensored. These 
starting values are substituted into the right side of equation (4.4), which 
yields the result for the first iteration,  β1.  These values are then substituted 
back into the right side, the first and second derivatives are recomputed, 
and the result is  β2. This process is repeated until the maximum change in 
the parameter estimates from one step to the next is less than .00000001. 
(This is an absolute change if the current parameter value is less than .01; 
otherwise, it is a relative change.)  
Once the solution is found, a convenient by-product of the Newton-
Raphson algorithm is an estimate of the covariance matrix of the 
coefficients, which is just )ˆ(1 jβI
 . This matrix, which can be printed by 
listing COVB as an option in the MODEL statement, is often useful for 
constructing hypothesis tests about linear combinations of coefficients. 
PROC LIFEREG computes standard errors of the parameters by taking the 
square roots of the main diagonal elements of this matrix. 
Maximum Likelihood Estimation:  Practical Details 
PROC LIFEREG chooses parameter estimates that maximize the 
logarithm of the likelihood of the data. For the most part, the iterative 
methods used to accomplish this task work quite well with no attention 
from the data analyst. If you’re curious to see how the iterative process 
works, you can request ITPRINT as an option in the MODEL statement. 
Then, for each iteration, PROC LIFEREG will print out the log-likelihood 
and the parameter estimates. When the iterations are complete, the final 
gradient vector and the negative of the Hessian matrix will also be printed 
(see the preceding section for definitions of these quantities).  
When the exponential model was fitted to the recidivism data, the 
ITPRINT output revealed that it took six iterations to reach a solution. The 
log-likelihood for the starting values was –531.1, which increased to  
! 9!
Proc Lifereg uses ordinary least squared (OLS) method to calculate this algorithm and treats the 
censored data as uncensored. 
During hypothesis testing, Proc Lifereg employs a chi-squared test, more specifically the Wald 
test and the equation is described as: 
              Equation 8 
Wald test examinations wether the coefficients of the corresponding varibles equal to 0 or 
otherwise. Additionally, Proc Lifereg provides a Lagrange multiplier chi-squared statsitics or 
simply a score statistic to test if the scale parameter is 1.   
Additionally, AFT model has the ability to produce predicted event time for any indicated set of 
covariate values which lacks in the other models. The AFT model satisfies parameters such that: !2 " = !D ED2"  for all t (time)             Equation 9 
This equation implies that the difference between 2 individuals or events is the rate at which they 
progress over time. For example, for human, it would be the rate they age. !2 is the survival 
probability of the expected, while !D is the survival probability of observed, and ED2 is a constant 
describing the relationship.  
Furthermore, If the dataset does not have censoring, AFT model estimates variables much like an 
ordinary linear regression and presented as: ABCFD = G, + G=%D= + ⋯+ GJ%DJ + KLD          Equation 10 
The error term in linear regression is typically assumed to have a normal distribution and since 
this is a logged equation, the error here has a log-normal distribution.  However, many survival 
datasets have censoring, and AFT model have different distribution to accomendate error term 
for such senerios and shown below:  
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authorities hold that if this hypothesis is not rejected, then there is no 
point in examining individual coefficients for statistical significance.) To 
calculate this statistic, we need only to fit a null model that includes no 
covariates. For a Weibull model, we can accomplish that with the 
following statement: 
MODEL week*arrest(0)= / D=WEIBULL; 
For the recidivism data, this produces a log-likelihood of  
–338.59. By contrast, the Weibull model with seven covariates displayed 
in Output 4.3 has a log-likelihood of –321.85. Taking twice the positive 
difference between these two values yields a chi-square value of 33.48. 
With seven degrees of freedom (the number of covariates excluded from 
the null model), the p-value is less than .001. So we reject the null 
hypothesis and conclude that at least one of the coefficients is nonzero.  
You can also test the same hypothesis with a Wald statistic, but that 
involves the following steps:  
1. request that the parameter estimates and their covariance matrix 
be written to a SAS data set  
2. read that data set into PROC IML, the SAS matrix algebra 
procedure  
3. use PROC IML to perform the necessary matrix calculations.  
(These calculations include inverting the appropriate submatrix of the 
covariance matrix and premultiplying and postmultiplying that matrix by 
a vector containing appropriate linear combinations of the coefficients.) 
That’s clearly a much more involved procedure.  
Wald statistics for testing the equality of any two coefficients are 
simple to calculate. The method is particularly useful for doing post-hoc 
comparisons of the coefficients of CLASS variables. Earlier we used a 
CLASS statement to include a three-category education variable in the 
model. As shown in Output 4.6, there is one chi-square test comparing 
category 3 with category 5 and another chi-square test comparing category 
4 with category 5. But there is no test reported for comparing category 3 
with category 4. The appropriate null hypothesis is that β3 = β4, where the 
subscripts refer to the values of categories. A Wald chi-square for testing 
this hypothesis can be computed by 
  
)ˆˆ(2)ˆ()ˆ(
)ˆˆ(
4,343
2
43
ββββ
ββ
CovVarVar +
 . (4.5) 
Estimates of the variances and covariances in the denominator are 
easily obtained from the covariance matrix that was requested in the 
MODEL statement. Output 4.7 shows a portion of the printed matrix.  
! 10!
Distribution of Ɛ Distribution of T 
Extreme value with 2 parameter Weibull 
Extreme value with 1 parameter Exponential 
Log-gamma Gamma 
logistic Log-logistic 
normal Log-normal 
Table 2 
Typical distributions used in AFT modeling are generalized gamma, Weibull, exponential, log-
normal, and log-logistic, which are explained further subsequently.  
The Gamma Model:  
The Gamma model makes the broadest assumption and is typically known as the generalized 
Gamma model. All following models are nested within the gamma model. The characteristic of 
gamma distribution is that it possesses a shape and a scale parameter. A table of shape and scale 
parameters relationships between other distributions and gamma model: 
Shape=1 Weibull 
Shape=1 and Scale=1 Exponential 
Shape=1 Log-normal 
  Table 3 
The Weibull Model: 
The Weibull model makes the second broadest assumption. The survival function presents: 
!D " = $%& − "D$MNOP QR             Equation 11 
The Weibull has a monotonic hazard function and is shown as: ABCℎ " = SABC" + G,∗ + G=∗%= + ⋯+ GJ∗%J          Equation 12 
! 11!
The relationship to OLS regression model is such that: G2∗ = MN0U  for j=1,…,k  and S = =U − 1 when G2 = 0, and if and only if G2∗ = 0 
    Equation 13  
In this model, when σ>1, hazard is decreased with time. When variance is between 0.5 and 1, the 
hazard is increasing at a decreasing rate [book]. When the variance is between 0 and 0.5, the 
hazard is increasing at an increasing rate. When σ=0.5, the hazard function displays a straight 
ling starting at the origin. Below is a graph illustrating different σ value after it’s transformed 
into α, and the equation presented above: 
    
                                                   Figure 1 Adapted from Allison et al 
The Exponential Model: 
As the simplest model within the series, this model assumes constant hazard over time, which is 
expressed as: 
 h(t)=λ               Equation 14 
Expressing the equation in a regression form: ABCℎ " = G,∗ + G=∗%= + ⋯+ GJ∗%J           Equation 15 
When equation 15 is compared with ordinary regression equation (equation 10), G2 = −G2∗. 
! 12!
There are more assumptions made by this model is that the error has an extreme-valued 
distribution same as the Weibull model, and contains variance equals to 1, which makes this 
model is a special case of Weibull distribution. This characteristic will make the scale parameter 
in Proc Lifereg equal to 1 as seen in table 3.  The distribution is not symmetrical and skewed to 
the left. 
The Log Normal Model: 
The log normal model has normal distribution with log transformation. It has a non-monotonic 
hazard function, which is different from the Weibull model. The hazard function is defined as: ABCℎ " = ABCℎ, "$MNO − G%           Equation 16 
This implies that when t=0, the hazard is also 0. Log-normal model is not a proportional hazard 
model and it does not have a closed form (unscaled normal distribution does not have a closed 
form). Therefore, l-normal model is presented in a logistic form typically as seen in equation 16. 
When the variance is large in this model, the hazard peaks rapidly and appears similar to Weibull 
and Log-logistic models. A graph of different variances with median=1 is presented below.  
    
                                       Figure 2 Adapted from Allison et al 
This model is best used for repeatable events. For example, in an event of buying a new car, 
immediately after the purchase, the chance of the same person buying another car is very low. 
Hence the left screwed peak where the hazard rate initially raises and eventually drops over time.  
! 13!
The log logistic model: 
As the name implies, the l-logistic model assumes that its error retains a logistic distribution. 
Typically, l-logistic model has a dichotomized dependent variable. This model also possesses an 
inverted U-shaped hazard curve as the l-normal and Weibull model. However, unlike l-normal 
model, this distribution is symmetrical with a mean of 0. 
The log logistic hazard function: ℎ " = WX W+ YZQ=[ W+ Y  where γ=1/σ and  \ = $%& − G, + G=%= + ⋯+ GJ%J  
    Equation 17 
The Survival Function of L-Logistic Model is seen as: ! " = ==[(W+) with the same restrictions the hazard function.      
                  Equation 18 
A logged regression view of the survival function: ABC ](+)=M](+) = G,∗ + G=∗%= + ⋯+ GJ∗%J − ^ABC"         Equation 19 G2∗ = GD/K for all i=1,…,k compared to ordinary regression. When σ<1, the hazard is similar to 
the log-normal hazard. When σ>1, the hazard is similar to the decreasing Weibull hazard. When 
σ=1, the hazard equal to λ at time 0 and eventually declines to 0 as time approaches infinity. A 
graph of σ over time is presented as: 
! 14!
  
    Figure 3 adapted from Allison et al 
The log-logistic model is best utilized with binary data such as categorical data of yes or no, and 
dead or alive, for instances.  
Here is a summary table with survival and hazard function of exponential, Weibull and Log-
logistic model, seen beneath:  
    
Table 4 adapted from Allison et al 
Different models are ranked by few fit statistics which are Akaike’s Information Criterion (AIC), 
corrected version of AIC (AICC), and Bayesian Information Criterion (BIC). The equations are 
seen as: 
AIC: AIC=-2logL+2k                        Equation 20 
AICC: AICC=AIC+`J(J[=)1MJM=             Equation 21 
BIC: BIC=-2logL+klogn            Equation 22 
AIC is a modified version of -2 log-likelihood and it penalizes models that have more covariates 
or more parameters. The benefit of AICC is its adequacy with small samples. Moreover, BIC 
penalizes for large sample number or additional covariates.  
On the left is a table containing the survival
and hazard functions for three of the more
commonly used distributions for survival
models: the exponential, Weibull, and log-
logistic distributions.
The exponential is a one-parameter distribu-
tion with a constant hazard l. The Weibull
and log-logistic distributions have two para-
meters l and p. Notice that the Weibull distri-
bution reduces to the exponential if p ¼ 1. The
probability density function for these distribu-
tions can be found by multiplying h(t) and S(t).
As an example, the Weibull probability density
function is shown on the left.
Typically for parametric survival models, the
parameter l is reparameterized in terms of
predictor variables and regression parameters
and the parameter p (sometimes called the
shape parameter) is held fixed. This is illu-
strated in the examples to come.
III. Exponential Example The first example we consider is the exponen-
tial model, which is the simplest parametric
survival model in that the hazard is constant
over time (i.e., h(t)¼ l). Themodel is applied to
the remission data (Freireich et al., 1963), in
which 42 leukemia patients were followed until
remission or censorship. Twenty-one patients
received an experimental treatment (coded
TRT ¼ 1) and the other 21 received a placebo
(codedTRT¼ 0).Thedata are listed inChapter 1.
The variable TRT is just a reverse coding of
the variable RX presented in Chapter 3.
Survival and Hazard Functions for
Selected Distributions
Distribution S(t) h(t)
Exponential exp("lt) l
Weibull exp("ltp) lptp"1
Log-logistic
1
1þ ltp
lptp"1
1þ ltp
f (t) ¼ h (t)S (t)
For example, Weibull:
f(t) ¼ lptp"1 exp("ltp)
because h(t) ¼ lptp"1 and
S(t) ¼ exp("ltp)
Typically in parametric models:
$ l reparameterized for
regression
$ p held fixed
Simplest parametric survival model:
Hazard function: h(t) ¼ l
(where l is a constant)
EXAMPLE
Remission data (n ¼ 42)
21 patients given treatment (TRT ¼ 1)
21 patients given placebo (TRT ¼ 0)
Presentation: III. Exponential Example 295
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The biggest downfall of Proc Lifereg method is the inability to include time-dependent 
covariates, in which case, Proc Phreg can be used and described below[12, 19]. 
Cox Regression-Proportional Hazards Model 
Named after Sir David Cox, whom first proposed this method through his paper “Regression 
Models and Life Tables” in the 1972 issue of Journal of the Royal Statistical Society, Series B, 
Cox Regression-Proportional Hazard Model has few advantage when compared with the 
Parametric model presented in Lifereg. This model does not require a distribution as Lifereg, 
thus making it semi-parametric. Due to this characteristic, Cox’s method is more robust than 
parametric model as well. Moreover, because its semi-parametric property, integration of time-
dependent covariates became much easier. 
In the software SAS, this model is included in the procedure, Proc Phreg, which has both 
proportional and non-proportional hazard models. The proportional hazard model is derived from 
the simple non-proportional hazard model. Below is the equation for non-proportional hazard 
model: 
hi(t)=λ0(t)exp(β1xi1+…+βkxik)          Equation 23 
Function hi(t) is the hazard of i at any given time t, and represented by a positive baseline hazard 
function h0(t) multiplies an exponential of covariates represented by X’s, 1 to k. 
And a logarithmic version of the same equation presented below: 
loghi(t)=α(t)+ β1xi1+…+βkxik            Equation 24 
Why it is a proportional hazard? The reason is that the hazard of one person is fixed from hazard 
of another person and the equation is seen as: 
aP +a0 + = $%& G= %D= − %2 + ⋯+ GJ %DJ − %2J          Equation 25 
! 16!
Proc Phreg utilizes maximum partial likelihood to estimate coefficient β. The benefit of using 
partial likelihood is that specifying baseline hazard function h0(t) is no longer needed. Equation 
of maximum partial likelihood model after maximize β is presented beneath: ABCbc = dD1D@= [ fD2$NO0]12@=            Equation 26 
The build in method of Proc Phreg which handles tiered models is the Breslow’s method. Also, 
Proc Phreg provides a likelihood ratio test, a score test which is the same as the log rank in 
Kaplan Meier method, and a Wald test which is discussed in AFT model for tiered data[12, 19].  
The benefit of Proc Phreg is the ability to optimize model using backward and forward selection 
which is utilized in the subsequent analysis. Backward selection considers the full model first, 
and deletes a predictor with the highest P-value one at a time till the model only consists of 
predictors that have less or equal to the indicated P-value. Forward selection includes the 
predictor with the lowest P-value first, then incorporates the next predictor with the lowest P-
value until all the predictors that have less or equal to the selected P-values are included in the 
model [20].   
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Chapter 2: Materials and Methods 
2.1 Purpose 
Several aims were established for current study. First, a full predictable survival model with the 
most suitable predictors is going to be constructed. Second, with the dramatic increase in HPV 
related OPSCC, P16 status will be investigated by itself, and with interactions of other available 
predictors. Last, other factors that may provide benefit to patient survival will be investigated as 
well. The data analysis will not necessarily be in above sequence.  
2.2 Dataset 
2.2.1 Overview 
The dataset consists of information regarding 300 HNSCC (OPSCC) patients obtained from 
Washington University in St. Louis. All patients in the dataset were treated and diagnosed in 
Barnes Jewish Hospital in St. Louis, MO, and the follow-ups were done in the same institute. All 
patients were not previous treated or diagnosed and the data is de-identified for patient privacy 
purpose. The study was conducted from June 1996 to June 2010, with follow-up through 
December 2014. Cancer statuses were gained through a database provided by the Department of 
Pathology, Otolaryngology, and Radiation Oncology. Comorbidity and outcome information 
were attained from the Oncology Data Services tumor registry. Vital statuses were acquired from 
electronic medical record which was further confirmed with the Social Security Death Index. 
There are 19 variables within the dataset and description and variable statistics can be seen in 
table 5 and 6.  
2.2.2 Categorical Variables 
! 18!
Categorical 
Variables Descriptions Categories % 
Anemic 
Status of 
anemia 
,! Missing (NA) 10.3 
0 No  74.0 
1 Yes 15.7 
Differentiation 
Differentiation 
Stage of 
cancers 
0 None 17.0 
1 Poorly Differentiated 56.7 
2 Moderately Differentiated 24.7 
3 Well differentiated 1.7 
Treatment5 
Types of 
treatment 
received by 
the cohort 
,! Missing (NA) 0.3 
1 Primary conformal radiation therapy  18.3 
2 Only surgery  8.7 
3 Primary radiation therapy 3.3 
4 Surgery+adjuvant radiation therapy 36.0 
5 Surgery+adjuvant conformal radiation therapy  33.3 
Radmodality 
Modality of 
radiation 
therapy 
0 None 9.3 
1 
Intensity-modulated radiation therapy(IMRT), 
external beam treatment 34.3 
2 
External beam therapy via a photon producing 
machine with beam energy ranging 6-10mv 12.7 
3 Treatment by external beam 30.0 
4 Definitive radiation therapy  2.0 
5 Post-operative adjuvant radiation therapy 8.3 
6 Post-operative adjuvant IMRT 2.0 
7 COMBINATION SPEC (< 2003) 0.3 
8 Definitive IMRT 0.7 
9 
Treatment delivered using a combination of 
photon and electron beams. 0.3 
Chem3 
Chemotherapy 
status of the 
patients 
,! Missing (NA) 0.3 
0 None 48.0 
1 Induction chemotherapy 11.7 
2 Concurrent chemotherapy 40.0 
Tobacco3 
Tobacco 
usage 
,! Missing (NA) 8.3 
0 None user 23.7 
1 Current user 34.0 
2 Former user 34.0 
Alcohol Alcohol usage 
,! Missing (NA) 11.0 
0 No  22.0 
1 Yes 67.0 
Recurrence ,! Missing (NA) 8.0 
! 19!
Recurrence of 
cancer 
0 No  77.7 
1 Yes 14.3 
Cancerstatus 
Cancer status 
of the cohort   
0 Free of this disease  80.7 
1 Not free of this disease 19.3 
Vitalstatus 
Status of dead 
or alive 
0 Alive 60.3 
1 Dead 39.7 
P16 
P16 protein 
status 
0 Negative 23.3 
1 Positive 76.7 
Sex 
Gender of the 
cohort 
0 Male 87.3 
1 Female 12.7 
Race 
Race of the 
cohort 
0 Others 1.7 
1 White 86.3 
2 Black 12.0 
ACE_27 
Adult 
comorbidity 
Evaluation 27 
index value 
,! Missing (NA) 1.7 
0 None 39.7 
1 Mild 37.7 
2 Moderate  14.0 
3 Severe 7.0 
Locoreg_fail 
Locro-
regional 
failure 
,!  Missing (NA) 0.7 
0 No 94.0 
1 Yes 5.3 
         Table 5 
2.2.3! Numerical Variables  
Variable Description 
Range Mean  
Median NA’s Units Lower upper  
HGB Hgb level  8.9 17.2 14.29 14.3 31 gm/dl 
Hematocrit Hematocrit level 8.0 50.0 41.79 41.80 31 RBC% 
Durationmo Time since diagnose 2.8 212.6 71.24 68.85 0 Months 
Age Age of  the patient  32.5 87.1 56.27 56.00 0 Years 
LN_positive 
Lymph nodes tested 
cancer positive 0.0 40.0 3.25 2.0 72 Counts 
Table 6 
2.3 Software 
Statistical software R was used for variable transformation and data subset. Command ifelse 
from package {base} was used to transform data into binary or categorical variables. Next 
! 20!
command cbind from the same package was used to combine desirable variables in to working 
dataset. Subsequently, dataset was exported as comma separated (csv) text via command 
write.csv in R package {utils}. 
SAS 9.4 statistical package was used for all the analysis and modeling. Proc Lifetest was utilized 
for Kaplan-Meier method. Proc Lifereg was used for AFT method, and Proc Phreg was applied 
for proportional hazards model.  
2.4 Procedures 
Initially, the dataset was explored as a whole, where a complete model including all the variables 
was developed. Cox proportional hazard regression with command Proc Phreg was utilized to 
achieve in building the full model. The response variable is Durationmo. The censored variable 
is Vitalstatus=0, and the predict variables were P16, Radmodality, Cancerstatus, Treatment5, 
LN_positive, Age, Sex, Anemic, Hematocrit, HGB, Chem3, Tobacco3, Alcohol, Recurrence, 
Locoreg_fail, ACE_27, Differentiation and Race. 
Furthermore, backward and forward selections were used to optimize the complete model, and 
only the significant variables specified at p≤0.15 for backward selections and p≤0.20 for forward 
selections were kept. The commands for those selections were slstay=0.15 and slentry=0.20, 
respectively. Additionally, Cox proportional hazard regression in Proc Phreg was used for 
backward and forward selection to determine which factors were significant for P16+ and P16− 
status separately. Also, P16 was treated as class (class P16) using Proc Phreg for backward 
elimination to see which factors are significant when P16 was treated as categorical variable and 
to see if there were any interactive terms for P16. 
Next, using Kaplan Meier method with syntax Proc Lifetest, survival graphs were generated for 
HNSCC survival rate with command Durationmo*Vitalstatus(0). Additionally, whole model 
! 21!
backward and forward selection was validated with test statement in Proc Lifetest 
(test<variables>), which provided a summary table of parameter estimates of all the variables, 
and a table of forward selection of each variable. Subsequently, P16 status was investigated as 
strata over Durationmo*Vitalstatus(0). This was achieved by using command strata P16. 
Survival probability graphs were also made for each variable. Test statement was used for 
specifying strata P16 as well.  Additionally, P16 was paired as strata with other variables. The 
variables were Age, Tobacco3, Recurrence, Locoreg_fail, Differentiation, and LN_positive.  
Moreover, variables that were found significant in the other models in this study, and in the 
previous studies mentioned in the introduction, or can potentially possess importance in patient 
survival were also investigated. The suspension of difference in demographic (race), various 
treatment options, types of chemotherapy and anemic status were analyzed accordingly. Next, 
the same variables were analyzed in subgroups of P16− and P16+ to investigate any differences 
in the subgroups. Survival graphs were generated for each step mentioned above.  
Following, the significant variables from the complete model selections were analyzed via 
various distributions in AFT model, which included Gamma, Weibull, exponential, L-normal, 
and L-logistic. Results and fit statistics were analyzed, and the best models were chosen for the 
complete survival model. This was achieved by using Proc Lifereg.  
All analysis was considered at the significance level of P≤0.05, unless noted otherwise. 
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Chapter 3: Results    
3.1 Cox Proportional Hazard Model 
During the initial data exploration, the full model with all the terms was developed using Cox 
proportional hazard model. During the process, there were 55 total events which corresponded to 
the number of patients that were deceased and not censored. Event used and censoring statistics 
can be seen below: 
Summary!of!the!Number!of!Event!and!Censored!Values!
Total! Event! Censored! Percent!
Censored!
173$ 55$ 118$ 68.21$
                                                                                                        Table 7 
3.1.1 Complete Model 
Parameter estimates and Hazard ratios were generated and shown beneath: 
Analysis of Maximum Likelihood Estimates 
Parameter DF Parameter Standard Chi-
Square 
Pr > 
ChiSq 
Hazard 
Estimate Error Ratio 
P16 1 -1.288 0.422 9.311 0.002 0.276 
Radmodality 1 -0.025 0.107 0.053 0.818 0.976 
LN_positive 1 0.059 0.029 4.235 0.040 1.061 
Treatment5 1 0.069 0.177 0.149 0.699 1.071 
Age 1 0.023 0.020 1.287 0.257 1.023 
Sex 1 -0.617 0.598 1.062 0.303 0.540 
Anemic 1 0.011 0.586 0.000 0.985 1.011 
Hematocrit 1 0.204 0.220 0.857 0.355 1.226 
HGB 1 -0.599 0.644 0.865 0.352 0.549 
Chem3 1 -0.208 0.190 1.204 0.273 0.812 
Tobacco3 1 0.288 0.206 1.954 0.162 1.333 
Alcohol 1 -0.440 0.384 1.311 0.252 0.644 
Recurrence 1 1.152 0.818 1.984 0.159 3.166 
Locoreg_fail 1 -0.747 0.673 1.233 0.267 0.474 
! 23!
Cancerstatus 1 1.085 0.855 1.610 0.205 2.960 
ACE_27 1 0.036 0.177 0.042 0.838 1.037 
Differentiation 1 0.481 0.256 3.513 0.061 1.617 
Race 1 -0.720 0.585 1.511 0.219 0.487 
      Table 8 
Likelihood ratio, score and Wald tests were performed for the whole model and all are shown 
significance: 
Testing Global Null Hypothesis: BETA=0 
Test Chi-Square DF Pr > ChiSq 
Likelihood Ratio 70.662 18 <.0001 
Score 108.526 18 <.0001 
Wald 70.429 18 <.0001 
         Table 9 
3.1.2 Backward Elimination: 
Next, stepwise backward selections of the whole model, P16+ status, and P16− status were 
generated at significance level of p≤0.15. The predictor with the highest P-value was removed 
one at the time until all of the parameters had at least p≤0.15.  
Whole model:   
The steps of removal are shown in a chart below:  
Summary of Backward Elimination 
Step Effect DF Number Wald Pr > ChiSq 
Removed In Chi-Square 
1 Anemic 1 17 0.000 0.985 
2 ACE_27 1 16 0.042 0.838 
3 Radmodality 1 15 0.054 0.816 
4 Treatment5 1 14 0.150 0.699 
5 Hematocrit 1 13 0.869 0.351 
6 HGB 1 12 0.047 0.829 
7 Race 1 11 0.786 0.375 
8 Chem3 1 10 0.642 0.423 
9 Alcohol 1 9 0.863 0.353 
10 Sex 1 8 1.354 0.245 
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11 Locoreg_fail 1 7 1.285 0.257 
12 Recurrence 1 6 1.386 0.239 
  Table 10 
After each parameter was removed, the chi-squares score and corresponding P-values were 
adjusted to fit the new model. Beneath is an output chart of the remaining parameters after the 
removal of insignificant factors: 
Analysis of Maximum Likelihood Estimates 
Parameter DF Parameter Standard Chi-
Square 
Pr > 
ChiSq 
Hazard 
Estimate Error Ratio 
P16 1 -1.019 0.332 9.435 0.002 0.361 
LN_positive 1 0.043 0.027 2.591 0.108 1.044 
Age 1 0.026 0.016 2.496 0.114 1.026 
Tobacco3 1 0.278 0.185 2.270 0.132 1.321 
Cancerstatus 1 1.906 0.326 34.244 <.0001 6.725 
Differentiation 1 0.420 0.235 3.190 0.074 1.522 
              Table 11 
Also, likelihood ratio, score and Wald test scores are significant for the optimized model and 
shown as: 
Testing Global Null Hypothesis: BETA=0 
Test Chi-Square DF Pr > ChiSq 
Likelihood Ratio 63.030 6 <.0001 
Score 101.906 6 <.0001 
Wald 69.812 6 <.0001 
          Table 12 
P16+ Status: 
For P16+ status with 6 degrees of freedom, likelihood ratio, score, and Wald tests were all 
significant at <.0001 and had Chi-squared score of 49.019, 88.432, and 53.358, respectively. 
Eleven predictors which failed to meet the criteria, were removed and the steps of elimination are 
in the order of Hematocrit, Anemic, Sex, Radmodality, ACE_27, Chem3, Treatment5, Age, 
Recurrence, Locoreg_fail, and Race.  Six predictors remained in the model and seen in Table 13:  
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Analysis of Maximum Likelihood Estimates 
Parameter DF Parameter Standard Chi-
Square 
Pr > 
ChiSq 
Hazard 
Estimate Error Ratio 
LN_positive 1 0.059 0.027 4.644 0.031 1.061 
HGB 1 -0.244 0.154 2.499 0.114 0.784 
Tobacco3 1 0.482 0.206 5.455 0.020 1.619 
Alcohol 1 -0.813 0.398 4.180 0.041 0.443 
Cancerstatus 1 2.872 0.438 42.918 <.0001 17.673 
Differentiation 1 0.533 0.262 4.129 0.042 1.704 
          Table 13 
P16− Status: 
With 7 degrees of freedom, the likelihood, score and Wald test for P16− status had Chi-square of 
18.534, 12.725, and 11.144 with P-value of 0.005, 0.0476 and 0.084, respectively.  Eleven 
predictors were removed and in the order of Cancerstatus, Race, Sex, LN_positive, Age, 
Differentiation, Treatment5, Recurrence, Alcohol, ACE_27, and Anemic. The six remaining 
significant factors are seen beneath: 
Analysis of Maximum Likelihood Estimates 
Parameter DF Parameter Standard Chi-
Square 
Pr > 
ChiSq 
Hazard 
Estimate Error Ratio 
Radmodality 1 0.859 0.322 7.101 0.008 2.360 
Hematocrit 1 -0.945 0.435 4.723 0.030 0.389 
HGB 1 2.786 1.287 4.682 0.031 16.214 
Chem3 1 -1.628 0.526 9.579 0.002 0.196 
Tobacco3 1 -1.556 0.602 6.673 0.010 0.211 
Locoreg_fail 1 -2.043 1.016 4.041 0.044 0.130 
   Table 14 
3.1.3 Forward Selection 
Stepwise forward selection was performed with restriction of p≤0.20. Starting with the most 
significant factor, the model was built based on including the parameter with the lowest P-value 
one at a time till all the p-values with p≤0.20 were included. Similar to backward elimination, 
when one new factor is included into the model, each parameter adjusts its Chi-squared score and 
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corresponding P-value accordingly to fit the new model.  Forward selection models were 
generated for the complete model, P16+ and P16−.  
Whole model: 
In the complete model selection, likelihood, score and Wald tests all were significant at 0.05 
level and the results are show below: 
Testing Global Null Hypothesis: BETA=0 
Test Chi-Square DF Pr > ChiSq 
Likelihood Ratio 67.350 6 <.0001 
Score 103.019 6 <.0001 
Wald 73.019 6 <.0001 
      Table 15 
Six predictors were selected at p≤0.20, and the other six were disregarded. The output of the 
parameters and the order of entry for each factor are presented below: 
Parameter DF Parameter Standard Chi-
Square 
Pr > 
ChiSq 
Hazard Order of  
Estimate Error Ratio Entry  
P16 1 -1.019 0.332 9.435 0.002 0.361 2 
LN_positive 1 0.043 0.027 2.591 0.108 1.044 6 
Age 1 0.026 0.016 2.496 0.114 1.026 5 
Tobacco3 1 0.278 0.185 2.270 0.132 1.321 3 
Cancerstatus 1 1.906 0.326 34.244 <.0001 6.725 1 
Differentiation 1 0.420 0.235 3.190 0.074 1.522 4 
         Table 16 
1)$ P16+ Status  
For P16+ population with 6 degree of freedom and P-value of <0.001, the likelihood, score and 
Wald test had results of 49.019, 88.432, and 53.358, respectively. Result for this model is shown 
below:  
Analysis of Maximum Likelihood Estimates 
Parameter DF Parameter Standard Chi-
Square 
Pr > 
ChiSq 
Hazard Order 
of  
Estimate Error Ratio Entry  
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LN_positive 1 0.059 0.027 4.644 0.0312 1.061 5 
HGB 1 -0.244 0.154 2.499 0.114 0.784 6 
Tobacco3 1 0.482 0.206 5.455 0.0195 1.619 2 
Alcohol 1 -0.813 0.398 4.180 0.0409 0.443 4 
Cancerstatus 1 2.872 0.438 42.918 <.0001 17.673 1 
Differentiation 1 0.533 0.262 4.129 0.0421 1.704 3 
                 Table 17 
P16− status 
For P16− population, with 6 degree of freedom and P-value of 0.0063, 0.0136, and 0.0444, the 
likelihood ratio, score and Wald test had results of 17.984, 16.027, and 12.918 respectively.  The 
output for parameter estimates and order of entry is show beneath: 
Analysis of Maximum Likelihood Estimates 
Parameter DF Parameter Standard Chi-
Square 
Pr > 
ChiSq 
Hazard Order of  
Estimate Error Ratio Entry 
Radmodality 1 0.356 0.190 3.505 0.061 1.427 3 
Treatment5 1 0.717 0.405 3.129 0.077 2.048 5 
Anemic 1 -1.061 0.738 2.065 0.151 0.346 6 
Chem3 1 -1.293 0.472 7.510 0.006 0.274 1 
Cancerstatus 1 1.750 0.760 5.301 0.021 5.757 2 
Race 1 -1.795 0.743 5.835 0.016 0.166 4 
      Table 18 
3.1.4! Class P16 
Additionally, P16 was treated as a class within Proc Phreg and a backward elimination at P≤0.20 
level.  With 4 degree of freedom the likelihood ratio, score and Wald test results are 53.868, 
75.277, and 60.431 with P-value <0.0001. The Parameter estimate is presented below: 
Analysis of Maximum Likelihood Estimates 
Parameter DF Parameter Standard Chi-
Square 
Pr > 
ChiSq 
Hazard 
Estimate Error Ratio 
Age 1 0.026 0.016 2.554 0.110 1.026 
Tobacco3 1 0.315 0.179 3.107 0.078 1.371 
Recurrence 1 1.878 0.294 40.784 <.0001 6.540 
Differentiation 1 0.692 0.207 11.168 0.001 1.999 
        Table 19 
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3.2 Kaplan-Meier Method 
3.2.1 Whole Model 
First, survival graphs were generated for HNSCC as a whole with Durationmo as the response 
variable and Vitalstatus=0 as the censoring. The graphs are presented below: 
 
                                          Figure 4 
 
To validate the backward and forward selection in Proc Phreg, test statement was used for Proc 
Lifetest which produced a composite of univariate estimate with standard deviation and 
corresponding chi-squared statistics, as well as forward selection of the whole model. This 
syntax is optimal with binary data such as many variables presented in this dataset. The 
univariate statistics with all parameters is described in table 20: 
Univariate Chi-Squares 
  Log-Rank Test  Wilcoxon Test 
Variable Test 
Stats 
SE Chi-
Square 
Pr 
>Chi 
Test 
Stats 
SE Chi-
Square 
Pr 
>Chi 
P16 12.55 2.20 32.57 <.0001 10.59 2.18 23.63 <.0001 
Radmodality -7.79 10.90 0.51 0.475 -5.33 9.18 0.34 0.561 
LN_positive -10.07 33.33 0.09 0.763 -11.66 27.91 0.17 0.676 
Treatment5 14.31 6.93 4.26 0.039 12.46 6.02 4.28 0.039 
Age -128.6 63.71 4.07 0.044 -98.35 53.89 3.33 0.068 
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Sex 1.69 2.42 0.49 0.486 1.76 2.02 0.76 0.384 
Anemic -2.27 2.58 0.78 0.377 -1.95 2.20 0.79 0.375 
Hematocrit 6.76 25.02 0.07 0.787 3.02 21.31 0.02 0.887 
HGB 5.47 9.00 0.37 0.544 3.51 7.63 0.21 0.646 
Chem3 13.36 7.27 3.38 0.066 11.35 6.10 3.46 0.063 
Tobacco3 -16.18 6.40 6.39 0.012 -13.05 5.24 6.21 0.013 
Alcohol -1.93 3.36 0.33 0.565 -2.16 2.80 0.60 0.439 
Recurrence -15.21 2.08 53.40 <.0001 -12.83 2.14 35.84 <.0001 
Locoreg_fail -1.55 1.19 1.69 0.193 -1.25 1.12 1.26 0.262 
Cancerstatus -14.83 1.71 75.08 <.0001 -12.75 1.90 45.03 <.0001 
ACE_27 -9.89 6.14 2.60 0.107 -8.49 5.26 2.61 0.106 
Differentiation -17.92 4.83 13.75 0.000 -14.89 4.11 13.14 0.000 
Race -2.69 1.95 1.90 0.168 -2.14 1.73 1.53 0.216 
         Table 20 
The forward selection produced by Proc Lifetest can be shown as: 
Forward Stepwise Sequence of Chi-Squares 
    Log-Rank Test  Wilcoxon Test 
DF Pr 
>Chi 
Variable Chi 
Increme
nt 
Pr> 
Increme
nt 
Variable Chi 
Increme
nt 
Pr> 
Increm
ent 
1 <.0001 Cancerstatus 75.08 <.0001 Cancerstatus 45.03 <.0001 
2 <.0001 P16 16.98 <.0001 P16 12.34 0.0004 
3 <.0001 Tobacco3 4.172 0.041 Tobacco3 5.176 0.023 
4 <.0001 Differentiation 3.107 0.078 Locoreg_fail 2.464 0.117 
5 <.0001 Locoreg_fail 2.205 0.138 Differentiation 1.797 0.180 
6 <.0001 Recurrence 2.791 0.095 Recurrence 1.848 0.174 
7 <.0001 Age 1.253 0.263 LN_positive 1.300 0.254 
8 <.0001 LN_positive 1.126 0.289 Age 1.226 0.268 
9 <.0001 Alcohol 0.703 0.402 Chem3 0.457 0.499 
10 <.0001 ACE_27 0.266 0.606 Alcohol 0.361 0.548 
11 <.0001 Chem3 0.248 0.618 Sex 0.305 0.581 
12 <.0001 Race 0.151 0.698 Race 0.214 0.644 
13 <.0001 Anemic 0.071 0.790 ACE_27 0.275 0.600 
14 <.0001 Hematocrit 0.034 0.853 Radmodality 0.193 0.660 
15 <.0001 HGB 0.309 0.578 Anemic 0.150 0.699 
16 <.0001 Sex 0.015 0.902 Treatment5 0.123 0.725 
17 <.0001 Radmodality 0.006 0.938 HGB 0.010 0.922 
18 <.0001 Treatment5 0.002 0.964 Hematocrit 0.060 0.807 
         Table 21 
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The significant variables that are ≤0.20 for both tests are Cancerstatus, P16, Tobacco3, 
Differentiation and Locoreg_fail.  
3.2.2 Strata P16 
Next, P16 was treated as strata by itself. The two groups had significantly different survival rate, 
which is presented in table 21: 
Test of Equality over Strata 
Test Chi-Square DF Pr > 
Chi-Square 
Log-Rank 68.48 1 <.0001 
Wilcoxon 64.86 1 <.0001 
-2Log(LR) 55.49 1 <.0001 
      Table 22 
Survival graph for P16+ and P16− were generated and shown in figure 5: 
  
                     Figure 5 
P16+ status has better survival rate than P16− patients for this dataset.  
To confirm results from the class statement of Cox proportional hazard model, test was used 
again with P16 desinated as strata, and result as followed: 
Univariate Chi-Squares  
  Log-Rank Test Wilcoxon Test 
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Variable Test 
Stats 
SD Chi-
Square 
Pr> 
Chi 
Test 
Stats 
SD Chi-
Square 
Pr 
>Chi 
Radmodality -4.49 10.77 0.174 0.677 -0.26 8.742 0.001 0.976 
LN_positive -25.2 30.39 0.685 0.408 -27.76 25.55 1.180 0.277 
Treatment5 8.096 7.346 1.214 0.271 5.667 5.678 0.996 0.318 
Age -115.0 69.65 2.725 0.099 -96.62 51.97 3.457 0.063 
Sex 1.356 2.364 0.329 0.566 1.302 1.937 0.452 0.501 
Anemic -0.501 2.746 0.033 0.855 -0.90 2.119 0.180 0.672 
Hematocrit -5.64 26.36 0.046 0.831 -2.828 20.60 0.019 0.891 
HGB 0.002 9.333 0.000 1.000 0.474 7.343 0.004 0.949 
Chem3 8.125 7.080 1.317 0.251 4.423 5.621 0.619 0.431 
Tobacco3 -12.85 6.145 4.374 0.037 -11.27 4.958 5.169 0.023 
Alcohol 0.922 3.050 0.091 0.762 0.167 2.596 0.004 0.949 
Recurrence -12.78 2.373 29.023 <.0001 -10.54 2.088 25.51 <.0001 
Locoreg_fail -0.105 1.591 0.004 0.948 -0.07 1.156 0.003 0.955 
Cancerstatus -12.97 2.028 40.925 <.0001 -10.57 1.885 31.423 <.0001 
ACE_27 -6.39 6.712 0.907 0.341 -5.64 5.035 1.257 0.262 
Differentiation -10.25 4.399 5.432 0.020 -8.103 3.648 4.933 0.026 
Race 0.687 2.294 0.090 0.765 0.521 1.665 0.098 0.754 
         Table 23 
Table of forward selection from Proc Lifetest is as followed: 
Forward Stepwise Sequence of Chi-Squares  
  Log-Rank Test Wilcoxon test 
DF Pr> Chi Variable Chi 
Incre
ment 
Pr> 
Increme
nt 
Variable Chi 
Incre
ment 
Pr> 
Increm
ent 
1 <.0001 Cancerstatus 40.92 <.0001 Cancerstatus 31.42 <.0001 
2 <.0001 Tobacco3 6.714 0.010 Tobacco3 6.107 0.014 
3 <.0001 Differentiation 3.072 0.080 Differentiation 2.697 0.101 
4 <.0001 Age 2.007 0.157 Locoreg_fail 1.678 0.195 
5 <.0001 Recurrence 2.243 0.134 Recurrence 1.990 0.158 
6 <.0001 Locoreg_fail 3.103 0.078 Age 1.591 0.207 
7 <.0001 LN_positive 2.510 0.113 LN_positive 1.916 0.166 
8 <.0001 Treatment5 1.168 0.280 Race 0.802 0.371 
9 <.0001 Chem3 1.775 0.183 Sex 0.659 0.417 
10 <.0001 Race 0.506 0.477 Chem3 0.480 0.488 
11 <.0001 Sex 0.341 0.559 Treatment5 0.426 0.514 
12 <.0001 Alcohol 0.294 0.588 Alcohol 0.343 0.558 
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13 <.0001 Radmodality 0.299 0.585 Radmodality 0.435 0.510 
14 <.0001 Anemic 0.062 0.803 ACE_27 0.385 0.535 
15 <.0001 Hematocrit 0.198 0.657 Anemic 0.335 0.563 
16 <.0001 HGB 0.425 0.514 Hematocrit 0.007 0.935 
17 <.0001 ACE_27 0.0002 0.988 HGB 0.214 0.644 
         Table 24 
The significant variables (p≤0.20) from forward selection were Cancerstatus, Tobacco3, 
Differentiation, Recurrence, Age, Locoreg_fail and LN_positive. Chem3 was positive for the log 
rank test and Age had slightly larger P-value than 0.20 in the Wilcoxon test.  
Following, P16 was treated as strata with other factors including Age, Tobacco3, Recurrence, 
Differentiation, Locoreg_fail and LN_positive. The chosen factors were the significance 
variables in the previous model. Age was grouped into 2 categories, <55 and ≥55. LN_positive 
was grouped into >10, between 10 and 20, and ≥20. The Log-Rank, Wilcoxon, and −2Log (LR) 
test results all had p<0.0001 for all groups and table for Chi-squared is presented below.  
Test of Equality over Strata (Chi-Square Test) 
Variables Age Tobacco3 Recurrence 
Locoreg
_fail Differentiation 
LN_ 
Positive 
Log-Rank 74.30 72.59 91.56 66.75 90.45 66.26 
Wilcoxon 69.89 65.88 84.90 63.85 79.81 63.32 
-2Log(LR) 64.52 69.87 68.49 54.17 71.84 47.38 
         Table 25 
The Survival probability graphs can be seen below: 
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         Figure 6 
For lymph nodes that were positive for cancer, the best survival rate group was the P16+ and 
lymph node found less than 10. Others are similar and some had not enough data points to 
determine.  
  
         Figure 7 
In these strata,  P16+ and less than 55 years old group had the best survival rate followed by 
P16+ and older than 55 years old group. The rest are simiar in survival rate.  
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          Figure 8 
For tobacco status, P16+ / nonsmokers have the best survival rate, Followed by P16+ / former 
smoker and P16+ / current smoker. P16− / current smoker had the worst survival rate.  
  
        Figure 9 
 
In this strata, P16+ / no recurrence of cancer had significantly better survival rate, followed by 
P16− / no recurrence group, then by P16+ / recurrence, and lastly is the P16− / recurrence group.  
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       Figure 10 
In this model, many did not have enough data to be accurate, such as the P16− / no 
differentiation, P16− / well differentiated and P16+ / well differentiated groups. The best 
survival rate group is P16+ / no differentiation followed by P16+ / poorly differentiated, then by 
P16+ / moderately differentiated, P16− / poorly differentiated and last, P16− / moderately 
differentiated.  
  
       Figure 11 
In this group, P16+/ has loco-regional failure and P16−/has loco-regional failure did not have as 
many data point. The survival rate seems to be separated by P16 status.  
3.2.3 Other Factors  
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Few variables of interest that were not selected from forward selection of Proc Lifetest were 
treated as strata to see if there were differences within strata. The reason for choosing these 
variables were to explored the effectiveness of different chemotherapy (Chem3), especially since 
Chem3 had P-value<0.20 in log rank test during forward selection of P16 strata, types of 
treatment (Treatment5), and difference in race are often questioned.  Also, as mentioned in the 
introduction, anemia is more prevalent in P16− group. The next question is that if anemia plays a 
role in survival and the problem is investigated subsequently. 
First Treatment5 was analyzed and test scores are presented below.   
Test of Equality over Strata 
Test Chi-
Square 
DF Pr > 
Chi-Square 
Log-Rank 43.700 4 <.0001 
Wilcoxon 51.017 4 <.0001 
-2Log(LR) 35.741 4 <.0001 
            Table 26 
Treatment stratified survival graphs are shown as: 
  
       Figure 12 
Treatment5 strata were significantly different, with stratum 1 (no treatment) had the lowest 
survival rate. Stratum 3 (surgery only) and 5 had the best survival rate and were similar to each 
other. Rest of the two strata were in the middle and were similar.  
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Next, Chem3 was treated as strata and the result is present as: 
Test of Equality over Strata 
Test Chi-
Square 
DF Pr > 
Chi-Square 
Log-Rank 24.214 2 <.0001 
Wilcoxon 30.397 2 <.0001 
-2Log(LR) 18.821 2 <.0001 
          Table 27 
  
       Figure 13 
Chem3 showed significant difference and all strata are not equal. Stratum Chem3=1 had the 
lowest survival rate which is induction chemotherapy. The other 2 strata showed similarity in 
survival probability, which were no chemotherapy and concurrent chemotherapy.  
Furthermore, Race was analyzed and hypothesis test statistics are below:  
Test of Equality over Strata 
Test Chi-Square DF Pr > 
Chi-Square 
Log-Rank 17.791 2 0.0001 
Wilcoxon 15.976 2 0.0003 
-2Log(LR)* 16.541 2 0.0003 
               Table 28 
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       Figure 14 
In stratum 0 which is the category of other, did not have enough data point and resulted in an 
empty stradum. As a reslut, -2Log(LR) statistics might not be correct since it assume 
proportionality. Ohterwise, the strata show significant in difference on the 0.05 level.  
Additionally, P16+ and P16− status were treated separately for the variables analyzed in the 
previous section, which include Treatment5, Chem3 and Race. A table of P16+ group is 
presented beneath: 
Test of Equality over Strata (P16+) 
  Treatment5 Chem3 Race 
Test Chi-
Square 
D
F 
Pr >Chi-
Square 
Chi-
Square 
DF Pr >Chi-
Square 
Chi-
Square 
DF Pr >Chi-
Square 
Log-Rank 15.395 4 0.004 10.8 2 0.005 3.135 2 0.209 
Wilcoxon 21.121 4 0.000 15.5 2 0.000 1.720 2 0.423 
-2Log(LR) 12.357 4 0.015 8.5 2 0.014 3.989 2 0.136 
        Table 29 
Survival graphs for all factors are seen below: 
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       Figure 15 
For P16+ subgroup, Race was the only factor that did not show significance which could be the 
result of not having enough data points for the analysis.  No treatment group had the worst 
survival outcome with rest of the strata appeared to have similar survival rate. Induction 
! 40!
chemotherapy had the worst survival rates which were similar to when chemotherapy were 
treated as strata without consideration of P16.  
Following are the test statistics for P16− group: 
Test of Equality over Strata (P16−) 
  Treatment5 Chem3 Race 
Test Chi-
Square 
DF Pr >Chi-
Square 
Chi-
Square 
DF Pr >Chi-
Square 
Chi-
Square 
DF Pr >Chi-
Square 
Log-Rank 13.599 4 0.009 3.963 2 0.138 0.644 1 0.422 
Wilcoxon 16.421 4 0.003 6.337 2 0.042 0.251 1 0.617 
-2Log(LR) 16.401 4 0.003 3.352 2 0.187 1.271 1 0.260 
       Table 30 
Survival graphs of each variable are as presented: 
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       Figure 16 
For P16− group, treatment5 showed most significance in difference of strata, followed by 
Chem3. Race was not significantly different for this group. Chemotherapy result is similar to 
P16+ group. For treatment, no treatment received had the worst survival rate for both with P16+ 
group had more difference.  
Lastly, Anemic was analyzed. First, anemic was treated as strata alone and the result is as 
followed: 
  
       Figure 17 
the log-rank, wilcoxon and -2log(LR) were all significant on the 0.05 level. Patients that were 
not anemic havd better survival rate.  
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Next, Anemia was analyzed against P16 status via strata as well and the log-rank, wilcoxon and -
2log(LR) were all significant with P<0.0001.  the results are as presented: 
  
       Figure 18 
For P16+ group, result as expected where none anemic group had better survival rate. However, 
for this dataset, patients who are P16−/ anemic, seemed to have better survival rate after 20 
months. This was further investigated where P16− status was specified and here is the result: 
Test of Equality over Strata 
Test Chi-
Square 
DF Pr > 
Chi-Square 
Log-Rank 1.35 1 0.246 
Wilcoxon 0.93 1 0.335 
-2Log(LR) 2.14 1 0.144 
 Table 31 
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       Figure 19 
There was a small difference but not significant at the 0.05 level. Anemic+ group seems to have 
slight better survival rate.  
3.3 Accelerated Fail Time Model 
3.3.1 Whole model with various distributions 
Various Factors that showed significance in previous models selections were considered, and 
after some analyze, six were used to fit the different distribution in AFT models. The variable 
chosen are P16, LN_positive, Age, Recurrence, Locoreg_fail, and Differentiation. The censoring 
statistics is shown as: 
Number of Observations Read 300 
Number of Observations Used 222 
Missing Values 78 
              Table 32 
All parameters were significant at P≤0.05 level in chi-squared test, and the parameter estimate 
can be seen in table 21: 
Analysis of Maximum Likelihood Parameter Estimates 
    Gamma Weibull Exponential L-normal L-logistic 
Parameter DF Estimate Estimate Estimate Estimate Estimate 
Intercept 1 6.910 7.640 8.490 6.762 6.933 
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P16 1 0.902 0.969 1.138 1.194 1.086 
LN_positive 1 -0.039 -0.062 -0.075 -0.062 -0.063 
Age 1 -0.025 -0.039 -0.049 -0.034 -0.035 
Recurrence 1 -1.219 -1.584 -1.865 -1.616 -1.577 
Locoreg_fail 1 0.787 0.792 0.951 1.103 0.945 
Differentiation 1 -0.386 -0.393 -0.484 -0.301 -0.328 
Scale 1 0.103 0.763 1.000 1.226 0.647 
Shape 1 10.628 1.311 1.000     
 Table 33 
3.3.2 Fit Statistics comparison 
Fit Statistics (logged response) 
  Gamma Weibull Exponential L-normal L-logistic 
-2 Log Likelihood 247.63 322.18 328.34 332.72 327.82 
AIC (smaller is better) 265.63 338.18 342.34 348.72 343.82 
AICC (smaller is better) 266.48 338.86 342.86 349.40 344.50 
BIC (smaller is better) 296.25 365.41 366.16 375.95 371.04 
         Table 34 
Comparing -2 Log likelihood, AIC, AICC and BIC results of the various distributions, Gamma 
distribution appears to be the most optimal, following by Weibull distribution. Models from 
those two distributions are the best fit and presented below.  
Gamma Distribution Model 
log h(t)=6.91Intercept+0.902XPP16 -0.039XLN_positive-0.025XAge-1.219XRecurrence+0.787XLocoreg_fail-
0.386XDifferentiation              Equation 27 
Weibull Distribution Model 
log h(t)=7.640Intercept+0.969XP16 -0.062XLN_positive-0.039XAge-1.584XRecurrence+0.792XLocoreg_fail-
0.393XDifferentiation              Equation 28 
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Chapter 4: Discussion 
Most of the results found in this study agreed with previous findings. Many treatment options, 
race, and tobacco use did not have enough data points to give a clear result. Especially when 
interactions with other factors were analyzed, most variables in this dataset have empty or few 
data points in one of the category or factor level, thus making interactive terms difficult to 
determine. Interactive terms were either inaccurate or not able to compute. However, this study 
provided some valuable information regarding HNSCC, and can potentially contribute more with 
follow up studies.  
In Cox proportional hazard method, during backward and forward selection, the significant 
factors came to be the same, which are P16, LN_positive, Age, Tobacco3, Cancerstatus, and 
Differentiation. From literature, P16 was found to have influence in survival rate where P16+ 
patients had better survival rate, which was mentioned in introduction such that P16+ individuals 
showed better survival rate amongst HNSCC patients. It’s intuitive to assume that number of 
lymph node found positive for cancer would have a relationship with survival. Age has 
traditionally found to be an influence in any cancer survival. Since younger patients have much 
better physical health. Moreover, current cancer status (Cancerstatus) is more likely to influence 
survival rate. Cancer free patients should have better survival rate. Lastly, stages of cancer, 
which is represented by Differentiation, can definitely play a role on survival rate, where if the 
cancer is in the further stage, the survival rate may not be as optimal compared with earlier stage. 
The variable selections for this model appear to be reasonable.   
For P16+ populations, which are predominately HPV+ demonstrated by previous studies, the 
significant factors from backward elimination are LN_positive, HGB, Tobacco3, Alcohol, 
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Cancerstatus, and Differentiation. The significant factors from forward selection are the same as 
backward. This is interesting since Tobacco and Alcohol use is typically related to P16− group. 
However, excess tobacco and alcohol use is ideal under any circumstances. The other factors are 
typical indications of cancer that were mentioned in the previous paragraph. Also HGB will be 
discussed in the next paragraph.  
For P16− group, backward elimination selected Radmodality, Hematocrit, HGB, Chem3, 
Tobacco3, and Locoreg_fail, while forward selection gave Radmodality, Treatment5, Anemic, 
Chem3, Cancerstatus and race. The difference might be that the P-values for backward and 
forward selections were slightly different, backward was at ≤0.15 and forward was at ≤0.20. 
Also, the methods which factors are selected are different. For backward elimination, the whole 
model is considered first. Within the whole model, there might be co-linearity or interaction of 
the terms that might affect the P-value of a factor, and P-value is the determine criteria for 
deletion. In forward selection, the most significant factor was included followed by the second 
and so on. This method cannot take account that the next factor selected is correlated to the other 
factors thus may not select the best factors for the whole model. For example, HGB has direct 
relations to anemic and Hematocrit since HGB, which represents hgb and it is a measurement of 
blood cell count; while anemic is measuring if someone is below the standard red blood cell 
count. Hematocrit is a measurement of blood cell count as well. With different methods of 
selection, one may select one instead of the other due to its mechanism. Here, the conclusion is 
that red blood cell count is related to P16− HNSCC patients, as mentioned in the introduction 
that P16− group are often anemic. One more interesting find is that hgb (HGB) was found 
significant for P16+ group as well suggesting that hgb level also plays a role in survival rate of 
P16+ group. Furthermore, treatment5, Race, Cancerstatus, Locoreg_fail, and Tobacco3 were the 
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other differences between forward and backward selection. Treatment5, which is the types of 
treatment, have similar categories as Chem3, which is the type of chemotherapy. Treatment5 was 
selected 2nd, it is possible that the model selected chem3 subsequently without consider the two 
might have relationship. While in backward elimination, treatment5 was the 7th to be deleted, 
Chem3 might affect the P-value of that. Further analysis using Proc Corr confirmed that Chem3 
is correlated with treatment5 and have P-value of <0.0001. Also, Cancerstatus showed 
correlation with treatment as well, which is intuitive. Radmodality is the different types of 
radiation and correlated with types of treatment. Additionally, the factors that were significant 
have effects on cancer survival in general or associated with P16 status. Tobacco use is typically 
associated with P53 HNSCC, which consists of a large percentage of P16− group. Locoregional 
failure (Locreg_fail) is cancer reappearance after chemotherapy in the local and regional area. 
Recurrence of cancer definitely decreases survival rate. Lastly, in category Race, most patients 
are in category 1 which is Caucasian. In subsequent analysis, race was further investigated.  
When P16 status was treated as a class against other factors and backward elimination was 
preformed, the significant factors were Age, Tobacco3, Recurrence and Differentiation. This 
suggests that these factors are significant when considered interaction with P16. This was further 
validated in Kaplan Meier method.  
Using Kaplan Meier method, backward and forward selection was further validated with forward 
selection in Proc Lifetest. The forward selection was utilized for the whole model as well as 
defining strata P16. In the whole model, the significant factors were Cancerstatus, P16, 
Tobacco3, Differentiation and Locoreg_fail. The difference factors between the Proc Phreg and 
Proc Lifetest were Age and LN_positive which were only in Proc Phreg, and Locroreg_fail 
which was only in Proc Lifetest. This is due to the difference in methods. Proc Phreg of Cox 
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proportional hazard method assumes proportionality while Proc Lifetest doesn’t. Age and 
LN_positive might fit proportional criteria, thus selected by Proc Phreg. Also, Kaplan Meier 
method is univariate, nonparametric test and good for binary data, while Cox proportional hazard 
method is semi-parametric. This might be the reason Locroreg_fail was selected for Proc 
Lifetest. Since Locroreg_fail is stored as binary data.  
When P16 was treated as strata over event time, P16+ group had much better survival rate, which 
is confluent with current studies. In the forward selection here, the significant factors (P≤0.20) 
were Cancerstatus, Tobacco3, Differentiation, Recurrence, Age, Locoreg_fail and LN_positive. 
This forward selection has more factors than the backward elimination of Proc Phreg. The 
reasons can be the difference in P-value and the different methods used as before. Furthermore, 
in forward selection of Proc Lifetest, two hypothesis tests are preformed which are the log rank 
and Wilcoxon. Chem3 was significant for the log rank test but not Wilcoxon. As mentioned in 
the introduction, Wilcoxon is a weighted test that favors earlier events. Chem3, which is 
different types of chemotherapy, could be conducted in the later times. Since chemotherapy is 
typically given after primary surgery.  In general, log rank test is far more popular. 
When P16 status was treated as strata with other factors which include Age, Tobacco3, 
Recurrence, Locoreg_fail, Differnetiation, and LN_positve, the results were as expected.  
For lymph nodes found positive (LN_positive), P16+ / less than 10 group had the best survival 
rate which was expected. Since P16+ group have better survival rate overall and less lymph node 
that has cancer cells, the better the survival for the patient. 
The P16 and Age strata were also within expectation with P16+ group having better survival rate 
and younger groups have better survival as well. Tobacco status and P16 strata also were 
expected with P16+ having better survival and nonsmokers have better survival. With 
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Differentiation, many strata did not have many data point. However each stratum is significantly 
different with P16+ status as the best and survival rate for different stages of differentiation is 
typical with no differentiations, which are the earlier stages of caner having the best survival rate 
to poorly then moderately. In the group of Loco-regional fail, the strata seem to follow the 
survival trend of P16 status but do not show difference within loco-regional fail.  
Since the dataset has relatively small number of patients, especially after censoring, several 
factor of interest were analyzed via strata in Proc Lifetest. Which were Chem3, Treatment5, 
Race, and Anemic. Treatment 5 was treated as strata over event time. It has 5 categories and 
maybe difficult to analyze with P16. Strata of treatment are significantly different with no 
treatment having the worst survival rate. The others are more or less similar in survival rate. 
However, types of treatment is still of interest since it is a factor that possess the most hope to 
patients. Therefore, chem3 was analyzed as strata. The category induction chemotherapy had the 
worst survival rate. Next race was analyzed and shoed difference with Caucasians having better 
survival rate.  
How would types of treatment, types of chemotherapy and race differ in survival rate for the P16 
groups? From the analysis, P16+ and P16− groups are similar in the strata. For treatment group, 
no treatment seemed to be worse in survival rate compared with the other treatment options, in 
P16+ groups, compared with P16− group, even the strata are significantly different, but not 
treatment group survival curve is much closer to the other groups. The interesting result is that 
Race is not significantly different in the subgroups when analyzed separately. This can be the 
result of not enough data in category 2 and 0.  
Anemic was treated as strata as well. Result was as expected where P16+ groups had better 
survival rate with P 16+/ non-anemic group having the best survival rate. The interesting result is 
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that P16−/anemic group had better survival rate than P16−/none anemic group. However this is 
not significantly different on the 0.05 level and can be the result of small dataset.  
For AFT models, gamma model followed by Weibull model had the least AIC, AICC, and BIC 
values which were expected since gamma model consists of the broadest assumption, and 
Weibull distribution model is derived from gamma model and the possesses the second broadest 
assumption. Exponential model assumes constant hazard which might not be the case for this 
study. L-normal is ideal for repeated events and this study is not designated for cancer 
repentance only. Last, L-logistic is best with binary data but this study has continuous variables 
as well as binary variables. In natural science, there are many unknown factors that should not 
make assumptions. Therefore, without may assumptions, gamma model should fit the dataset the 
best.  
In conclusion, factors affected HNSCC (OPSCC) were as expected. Having treatment of any 
kind increase the chance of survival. In chemotherapy, induction chemo has the worst survival 
rate for this dataset. The early stages of HNSCC have better survival rate than the later stages. 
Recurrent cancer patients have worse survival rate. Younger patients have better survival rate as 
well. Similar to other studies, P16+ status had better survival rate and far better survival 
predictor than other factors.  
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